Clinical Trial Update: The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of JS002 for primary hypercholesterolemia and mixed hyperlipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• JS002

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Hyperlipemia | Phase 3 | Status: COMPLETED